EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis

Amir Tavakkol iD, Janet C DuBois, Aditya K Gupta iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00682-24 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Amir Tavakkol und 2 weiteren Autor:innen. Beteiligte Einrichtung: Moberg Pharma AB, Bromma, Sweden. Hauptthemen laut MEDLINE: Terbinafine, Onychomycosis, Antifungal Agents, Administration, Topical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topical antifungals may be considered to treat onychomycosis with minimal risk of systemic side effects. In this study, we assess the safety, tolerability, systemic exposure, and pharmacokinetic characteristics of topical terbinafine hydrochloride 10% solution (MOB015B) in adults with moderate-to-severe onychomycosis. Clinically and mycologically confirmed patients with toenail onychomycosis ( N = 20) were enrolled in this single-center, open-label study . Each patient had ≥50% involvement of both great toenails and at least four additional toenails affected. MOB015B was applied once daily to all toenails for 28 days. Blood was drawn on days 1, 14, and 28. Plasma concentrations of MOB015B after the first dose were quantifiable in all subjects by 24 h. Steady-state levels in plasma were reached by day 28. The mean systemic exposure on day 28 of 0.72 ng/mL for maximum plasma concentration (C max ) was approximately 2,000 times lower than the mean plasma level of 1.39 µg/mL seen after oral administration of 250 mg terbinafine for 28 days. Adverse events (five patients), such as headache ( n = 3), seasonal allergy ( n = 1), and neck pain ( n = 1), were considered unrelated to MOB015B; no application site reactions or study discontinuations due to an adverse event were observed. MOB015B applied to all affected toenails under maximal usage conditions for 28 days demonstrated very low levels of terbinafine in plasma (C max

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TerbinafineOnychomycosisAntifungal AgentsAdministration, TopicalHumansMaleMiddle AgedFemaleAdultAgedNaphthalenes

Stichwörter der Autor:innen

onychomycosispharmacokineticsterbinafine

Substanzen

TerbinafineAntifungal AgentsNaphthalenes

Autor:innen und Institutionen

  • Moberg Pharma AB, Bromma, Sweden.
  • DermResearch Inc., Austin, Texas, USA.
  • Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Mediprobe Research Inc., London, Ontario, Canada.

ORCID-Profile: Amir Tavakkol, Aditya K Gupta

Zitieren

APA

Tavakkol, A., DuBois, J. C., & Gupta, A. K. (2024). Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00682-24

Vancouver

Tavakkol A, DuBois JC, Gupta AK. Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00682-24

BibTeX
@article{Tavakkol2024,
  author = {Tavakkol, Amir and DuBois, Janet C and Gupta, Aditya K},
  title = {Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00682-24}
}
Kostenlos starten →